| |
|
|
|
Adamas Pharma  
|
|
3.78 -0.12 (-0.03%) |
10-21 14:29 |
|
Open: |
3.87 |
Pre close: |
3.9 |
Target:
|
5.41 
|
|
High: |
3.95 |
Low: |
3.76 |
Resistance:
|
4.63
5.16
|
|
Volume: |
73,190 |
Market Cap: |
107M |
Support:
|
3.76
3.13
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
4.21
|
MACD |
MACD(12,26):
|
-0.08 |
|
MA(20): |
4.35 |
Signal(12,26,9): |
-0.01 |
|
MA(100): |
3.72  |
Stochastic Oscillator |
%K(14,3):
|
11.42 |
|
MA(250): |
4.05 |
%D(3): |
26.32 |
|
Average Volume(K) |
3-Month: |
51687
|
52-Week |
High:
|
7.45 |
|
10-Days: |
18489 |
Low: |
1.90 |
|
RSI |
RSI(14):
|
33.72 |
Change(%): |
-0.9 |
|
Financials, Statistics and Valuation |
|
EPS |
-2.784 |
Return on Equity (ttm) |
-851.3 |
Shares Out. (M) |
28.28 |
|
EPS Est. Current Year |
-3.770 |
Return on Assets (ttm) |
-23.4 |
Shares Float (M) |
19.02 |
|
EPS Est. Next Year |
-3.420 |
PEG Ratio |
0.00 |
% Held by Insiders |
2.81 |
|
EPS Est. Next Quarter |
-1.170 |
Qtrly Rev. Growth |
48.1 |
% Held by Institutions |
79.07 |
|
Forward EPS |
-3.800 |
Gross Profit (p.s.) |
1.845 |
Shares Short (K) |
787 |
|
Book Value (p.s.) |
-0.860 |
EBITDA (p.s.) |
-2.168 |
P/E |
-1.36 |
|
Sales Per Share |
2.248 |
Qtrly Earnings Growth |
0.00 |
P/BV |
-4.41 |
|
Profit Margin |
-122.52 |
Operating Cash Flow
(M) |
-66.50 |
P/S |
1.69 |
|
Operating Margin |
-98.02 |
Levered Free Cash Flow
(M) |
-44.21 |
P/CF |
-1.61 |
|
|
|
|
|
|
